-NONE-

THE PURPOSE OF THIS AWARD IS TO ADVANCE THE DEVELOPMENT OF ISOLA'S NEBULIZATION THERAPY, A MEDICAL COUNTERMEASURE DESIGNED TO PREVENT AND TREAT PULMONARY FOAM THE INHALATION OF CHEMICAL AGENTS CAUSES.

BARDA - ASPR / DAAPPO / BARDA DCMA·Dec 2025 — Dec 2025

$7.5M

Total Obligated

AWARDED541715

Single Signal1 signal

1 modification·Bidders unknown

Signal Analysis

Click any signal to see the evidence

8 other signals analyzed — no deviations detected

Financial Summary

$7.5M

Total Obligated

$7.5M

Current Value

$7.5M

Potential Value

Timeline

Dec 2025

Award Date

Dec 2025

Completion Date

—

Duration

FY2026

Fiscal Year

Competition

—

Bidders

—

Contracting Details

Awarding AgencyBARDA - ASPR / DAAPPO / BARDA DCMA

Awarding OfficeBARDA - ASPR / DAAPPO / BARDA DCMA

NAICS541715

Place of Performance55410

Created Byfpds_records

Procurement OfficeAvailable in Enterprise plan

Modifications

Original: $7.5MChange orders: $0+0%

Mod	Date	Amount	Cumulative	Action
0	Dec 2025	$7.5M	$7.5M	initial_award

Awarded To

ISOLA THERAPEUTICS INC

UEI: M3QDM72NME75

View company profile →

Similar Contracts

80JSC019C0012

Unknown — ORION PRODUCTION AND OPERATIONS CONTRACT

$3.3B

-NONE-

Unknown — WORK REQUIRED FOR THE DESIGN, DEVELOPMENT, MANUFACTURE, TEST...

$3.0B

89243126CSC000213

SC OAK RIDGE OFFICE — Management and Operating Contractor for the Thomas Jefferson...

$1.8B

80JSC022DA035

Unknown — ENGINEERING AND SCIENTIFIC PRODUCTS AND TECHNICAL SERVICES A...

$1.2B

80KSC023DA016

Unknown — CONSOLIDATED OPERATIONS, MAINTENANCE, ENGINEERING, AND TEST ...

Statistical observations derived from public procurement data. Patterns identified do not constitute findings, accusations, or allegations of wrongdoing. All analysis is based on publicly available records and requires independent verification before any action is taken. This is not legal advice. Terms of Service